Roche has signed its second molecular glue deal in a month, this time paying $50 million upfront to Monte Rosa Therapeutics for the use of its QuEEN platform to target cancer and neurological diseases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback